Related Experiment Video

Updated: Oct 13, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.2K

Pyrolyzed deketene curcumin controls regulatory T cell generation and gastric cancer metabolism cooperate with

Takashi MaruYama1,2,3, Hirofumi Miyazaki3, Yun-Ji Lim1

  • 1Mucosal Immunology Section, National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Health, Bethesda, MD, United States.

Frontiers in Immunology
|February 23, 2023
PubMed

Insights

Pyrolyzed deketene curcumin GO-Y022 inhibits gastric tumor growth by restricting glucose metabolism and promoting anti-tumor immunity. This compound reduces L-lactate production and Treg generation in gastric cancer cells.

Area of Science:

  • Immunology
  • Oncology
  • Biochemistry

Background:

  • Pyrolyzed deketene curcumin GO-Y022 demonstrates anti-carcinogenic effects in gastric cancer models.
  • The impact of GO-Y022 on tumor-induced immune suppression, particularly regulatory T cells (Tregs), remains unclear.

Purpose of the Study:

  • To investigate the effect of GO-Y022 on Treg generation in gastric cancer.
  • To elucidate the mechanisms by which gastric tumor cells modulate GO-Y022's anti-Treg activity.

Main Methods:

  • Investigated GO-Y022's effect on Treg generation in vitro with transforming growth factor beta 1 (TGF-β).
  • Analyzed L-lactate production by gastric tumor cells treated with GO-Y022.
  • Co-cultured naïve CD4+ T cells with GO-Y022 treated gastric tumor cells.
  • Assessed the impact of 2-deoxy-d-glucose (2DG), a glycolysis inhibitor, in combination with GO-Y022.

Main Results:

  • GO-Y022 inhibited Treg generation induced by TGF-β but had limited effect on established Foxp3+ Tregs in the tumor microenvironment.
  • Gastric tumor cells treated with GO-Y022 increased L-lactate production, counteracting GO-Y022's inhibitory effect on Treg generation.
  • Co-culture with GO-Y022 treated tumor cells enhanced Treg generation.
  • Combination treatment with GO-Y022 and 2DG reduced L-lactate production and Treg generation.
  • Combined therapy enhanced GO-Y022-induced tumor cell death.

Conclusions:

  • GO-Y022, when combined with restricted glucose metabolism (e.g., using 2DG), effectively inhibits gastric tumor cell survival.
  • This combined approach promotes anti-tumor immunity by reducing Treg generation and L-lactate production.
Keywords:
adenosine triphosphateglycolysisregulatory T cellsstomach neoplasmstumor microenvironment

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.2K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

814

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...